Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naive Patients With Type 2 Diabetes (T2DM).

Next Previous
X
Search
Trial Profile

A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naive Patients With Type 2 Diabetes (T2DM).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Liraglutide (Primary) ; Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms SAFEGUARD

    • Most Recent Events

    • 20 Dec 2016 Primary endpoint has been met. (Changes from baseline following 12-week treatment with DPP-4i Sitagliptin or GLP-1RA liraglutide (long-term effects) on pancreatic exocrine function (chymotrypsin)) as per article published in the Diabetes Care.
    • 20 Dec 2016 Primary endpoint has not been met. (Changes from baseline following 12-week treatment with GLP-1RA liraglutide or DPP-4i Sitagliptin (long-term effects) on pancreatic exocrine function, (lipase activity measured as cumulative13C recovery)) as per article published in the Diabetes Care.
    • 20 Dec 2016 Results published in the Diabetes Care

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top